Edited for not offending:
I can wait for a Christmas
Edited for not offending:
I can wait for a Christmas present to show itself this year. Nader said... approval possible by end of year. Which will be first? Covid or HIV? I am good with that race. I am also good with if he is a month off due to whatever reason that could come up. Some complainers just blow me away. Like they could jump in and run this company better. If that’s who you are?
We didn’t have the best news we expected today. But it was more news that de-risks our investment in my opinion. The things I liked...
Trial continues with no major modification! That’s huge! Slight added mod of 42 days to improve our strength in the next interim look. I am good with this help. De-risking!
Looks like HIV in U.K.,EU and Canada is going to be submitted soon. Like a week for U.K. and the next week for Canada. This is great news... yet we hear complaining? Whining? Really? More de-risking.
I am happy to hear our updates on other indications and to see our focus is moving forward in all that matters to the investor. MTNBC, Basket Trial (BTD?), GVHD, Nash and long haulers. I hope these are not slowed and continue to further the bottom line of this company. I am excited still to see just how many indications will get approved. That’s why I will stay in this investment.
Covid is a possible big time revenue depending on how we can ramp up our supply chain. That’s the bottle neck we have. Solve that problem and look out on the revenue front. I am a firm believer we won’t have a long term vaccine. Sad about it but reality is this Covid Coronavirus mutates like HIV. Not encouraging.
Ask Gilead what they thought they could make on Covid. There are just another domino that just fell in the wrong direction. Opens up a pretty big market for a drug that works and we know we do. Just need the p value to show it. It’s a numbers game and we have a small budget in comparison to others but somehow on our beer budget we will be popping champagne bottles. Just imagine that. Our time is coming in many ways. If you were here for just Covid. You haven’t done enough D&D and should know the over 60 possible indications this inflammation controller/ autoimmune regulator will be approved for. Yet we have reasons to complain... like I said before. The complainers can leave and you won’t be missed... that’s a guarantee. Time is still on our side. We are still in the lead for first approval in severe/critical. But that doesn’t really matter first or second. There will be lots of revenue for whomever is in the approval club when all is said and done.
Now the whiners can pick apart my positive post... will it make me sell shares? Nope...
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...
Continue Reading
Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...
Continue Reading
Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...
Continue Reading
KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...
Continue Reading
The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...
Continue Reading
Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...
Continue Reading
When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...
Continue Reading
Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....
Continue Reading
Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...
Continue Reading
Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...
Continue Reading
Top 5 Most Recently Viewed Articles
XPENG Unveils the All-New P7 Sports Sedan XPENG has recently captured the attention of the automotive industry by unveiling the first images of its next-generation P7 sports sedan, a stunning evolution of its well-respected electric vehicle. This latest model embodies a daring and emotionally resonant design, continuing the company's commitment to excellence in the...
Continue Reading
Millicom's Share Repurchase Initiative Millicom, a leading telecommunications provider known for its dedication to enhancing shareholder value, recently launched a share repurchase program. This initiative, announced on a significant date, sets the stage for Millicom to strengthen its financial position and reward its investors more effectively. Details of the Share...
Continue Reading
TransformativeMed Forms Strategic Partnership with Vantiq TransformativeMed Now Positioned as Go-To Platform for Intelligent Systems and AI Leadership TransformativeMed, known for its exceptional CORES Platform, has established a strategic collaboration with Vantiq, a global leader in real-time AI and intelligent systems platforms. This partnership aims to position...
Continue Reading
The Row's Ambitious Next Steps The Row, an innovative mixed-use development, is on the brink of a transformative phase, focusing on enriching the far southeast area with vibrant retail, dining, and hotel options. This community-driven effort aims to elevate the quality of living for residents while creating a bustling hub for visitors. New Name, New Vision Previously...
Continue Reading
Introduction to Carbon Capture Technologies The carbon capture, utilization, and storage (CCUS) market offers an exciting glimpse into the future of energy sustainability. As the world increasingly confronts the challenges of climate change, new innovations in CCUS are becoming vital. Experts anticipate that this market will expand significantly, with projections...
Continue Reading